Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,060

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus

Open access
Spechler, Stuart J., Sharma, Prateek, Souza, Rhonda F., Inadomi, John M., Shaheen, Nicholas J.·2011·Gastroenterology
DOI 10.1053/j.gastro.2011.01.031
Open this paper in CoChat — free account

Abstract

The aim of evidence-based medicine is to improve the quality of health care by integrating the best research evidence with clinical expertise and patient values. Evidence-based clinical guidelines are sets of recommendations intended to assist health care providers and patients in selecting the best management for common clinical situations while accounting for patient-specific circumstances. In addition to providing optimal, patient-centered care and improved outcomes, guidelines can reduce practice variability, identify gaps in evidence, enhance efficiency of resource use, and facilitate development of outcome and performance measures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2011.01.031

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 315

  1. Sharma, 2004, A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop, Gastroenterology, 127, 310, 10.1053/j.gastro.2004.04.010 · doi:10.1053/j.gastro.2004.04.010
  2. Vakil, 2006, The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus, Am J Gastroenterol, 101, 1900, 10.1111/j.1572-0241.2006.00630.x · DOI · Paper page
  3. Wang, 2008, Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus, Am J Gastroenterol, 103, 788, 10.1111/j.1572-0241.2008.01835.x · DOI · Paper page
  4. Shaheen, 2009, Barrett's oesophagus, Lancet, 373, 850, 10.1016/S0140-6736(09)60487-6 · DOI · Paper page
  5. McClave, 1987, Early diagnosis of columnar-lined esophagus: a new endoscopic criterion, Gastrointest Endosc, 33, 413, 10.1016/S0016-5107(87)71676-9 · doi:10.1016/s0016-5107(87)71676-9
  6. Choi do, 2002, Endoscopically observed lower esophageal capillary patterns, Korean J Intern Med, 17, 245, 10.3904/kjim.2002.17.4.245 · doi:10.3904/kjim.2002.17.4.245
  7. Vianna, 1987, Normal venous circulation of the gastroesophageal junction, Gastroenterology, 93, 876, 10.1016/0016-5085(87)90453-7 · doi:10.1016/0016-5085(87)90453-7
  8. Paull, 1976, The histologic spectrum of Barrett's esophagus, N Engl J Med, 295, 476, 10.1056/NEJM197608262950904 · DOI · Paper page
  9. Hayward, 1961, The lower end of the oesophagus, Thorax, 16, 36, 10.1136/thx.16.1.36 · DOI · Paper page
  10. Spechler, 2004, Intestinal metaplasia at the gastroesophageal junction, Gastroenterology, 126, 567, 10.1053/j.gastro.2003.11.061 · doi:10.1053/j.gastro.2003.11.061
  11. Chandrasoma, 1997, Pathophysiology of Barrett's esophagus, Semin Thorac Cardiovasc Surg, 9, 270
  12. Liu, 2009, Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium, Am J Gastroenterol, 104, 816, 10.1038/ajg.2009.85 · DOI · Paper page
  13. Hahn, 2009, Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus, Am J Surg Pathol, 33, 1006, 10.1097/PAS.0b013e31819f57e9 · DOI
  14. Takubo, 2009, Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma, Hum Pathol, 40, 65, 10.1016/j.humpath.2008.06.008 · DOI · Paper page
  15. Shaheen, 2000, Is there publication bias in the reporting of cancer risk in Barrett's esophagus?, Gastroenterology, 119, 333, 10.1053/gast.2000.9302 · DOI · Paper page
  16. Sharma, 1998, Short segment Barrett's esophagus, Am J Gastroenterol, 93, 1033, 10.1111/j.1572-0241.1998.00324.x · doi:10.1111/j.1572-0241.1998.00324.x · Paper page
  17. Sharma, 2006, The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria, Gastroenterology, 131, 1392, 10.1053/j.gastro.2006.08.032 · DOI · Paper page
  18. Robertson, 1988, Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus, Br J Surg, 75, 760, 10.1002/bjs.1800750813 · DOI
  19. Reid, 1992, Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort, Gastroenterology, 102, 1212, 10.1016/0016-5085(92)90758-Q · doi:10.1016/0016-5085(92)90758-q · Paper page
  20. Bartlesman, 1992, Barrett's oesophagus, Eur J Cancer Prev, 1, 323, 10.1097/00008469-199206000-00008 · DOI
  21. Aldulaimi, 2005, Barrett's surveillance is worthwhile and detects curable cancers, Eur J Gastroenterol Hepatol, 17, 943, 10.1097/00042737-200509000-00010 · doi:10.1097/00042737-200509000-00010
  22. Chang, 2007, The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review, Ann Surg, 246, 11, 10.1097/01.sla.0000261459.10565.e9 · doi:10.1097/01.sla.0000261459.10565.e9
  23. Thomas, 2007, Meta analysis: cancer risk in Barrett's oesophagus, Aliment Pharmacol Ther, 26, 1465, 10.1111/j.1365-2036.2007.03528.x · doi:10.1111/j.1365-2036.2007.03528.x
  24. Yousef, 2008, The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis, Am J Epidemiol, 168, 237, 10.1093/aje/kwn121 · DOI · Paper page
  25. Cook, 2007, Risk of mortality and cancer incidence in Barrett's esophagus, Cancer Epidemiol Biomarkers Prev, 16, 2090, 10.1158/1055-9965.EPI-07-0432 · DOI
  26. Cooper, 2006, Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence, Aliment Pharmacol Ther, 23, 727, 10.1111/j.1365-2036.2006.02825.x · DOI
  27. Gatenby, 2009, Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus, Dis Esophagus, 22, 133, 10.1111/j.1442-2050.2008.00886.x · DOI
  28. Alcedo, 2009, Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance, Dis Esophagus, 22, 239, 10.1111/j.1442-2050.2008.00908.x · doi:10.1111/j.1442-2050.2008.00908.x
  29. Anderson, 2003, Mortality in Barrett's oesophagus: results from a population based study, Gut, 52, 1081, 10.1136/gut.52.8.1081 · doi:10.1136/gut.52.8.1081
  30. Eckardt, 2001, Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation, Am J Med, 111, 33, 10.1016/S0002-9343(01)00745-8 · doi:10.1016/s0002-9343(01)00745-8
  31. Moayyedi, 2008, Mortality rates in patients with Barrett's oesophagus, Aliment Pharmacol Ther, 27, 316, 10.1111/j.1365-2036.2007.03582.x · doi:10.1111/j.1365-2036.2007.03582.x
  32. Solaymani-Dodaran, 2005, Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study, Am J Gastroenterol, 100, 2616, 10.1111/j.1572-0241.2005.00340.x · doi:10.1111/j.1572-0241.2005.00340.x
  33. Rana, 2000, Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance, Dis Esophagus, 13, 28, 10.1046/j.1442-2050.2000.00069.x · doi:10.1046/j.1442-2050.2000.00069.x
  34. Van der Burgh, 1996, Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus, Gut, 39, 5, 10.1136/gut.39.1.5 · doi:10.1136/gut.39.1.5
  35. Mayne, 2001, Nutrient intake and risk of subtypes of esophageal and gastric cancer, Cancer Epidemiol Biomarkers Prev, 10, 1055
  36. Crockett, 2009, Health-related quality of life in patients with Barrett's esophagus: a systematic review, Clin Gastroenterol Hepatol, 7, 613, 10.1016/j.cgh.2009.02.024 · DOI
  37. Wiklund, 1998, Quality of Life in Reflux and Dyspepsia patients, Eur J Surg Suppl, 41
  38. Eypasch, 1995, Gastrointestinal Quality of Life Index: development, validation and application of a new instrument, Br J Surg, 82, 216, 10.1002/bjs.1800820229 · DOI · Paper page
  39. Gerson, 2007, Does cancer risk affect health-related quality of life in patients with Barrett's esophagus?, Gastrointest Endosc, 65, 16, 10.1016/j.gie.2006.05.018 · DOI
  40. Shaheen, 2005, The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program, Gastroenterology, 129, 429, 10.1016/j.gastro.2005.05.055 · DOI
  41. Shaheen, 2005, Effect of a new diagnosis of Barrett's esophagus on insurance status, Am J Gastroenterol, 100, 577, 10.1111/j.1572-0241.2005.41422.x · doi:10.1111/j.1572-0241.2005.41422.x
  42. Abrams, 2008, Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy, Clin Gastroenterol Hepatol, 6, 30, 10.1016/j.cgh.2007.10.006 · doi:10.1016/j.cgh.2007.10.006
  43. Edelstein, 2009, Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study, Am J Gastroenterol, 104, 834, 10.1038/ajg.2009.137 · DOI
  44. Cooper, 2006, Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence, Aliment Pharmacol Ther, 23, 727, 10.1111/j.1365-2036.2006.02825.x · DOI
  45. Campos, 2001, Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease, Arch Surg, 136, 1267, 10.1001/archsurg.136.11.1267 · doi:10.1001/archsurg.136.11.1267
  46. Falk, 2005, Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer, Clin Gastroenterol Hepatol, 3, 1089, 10.1016/S1542-3565(05)00606-3 · doi:10.1016/s1542-3565(05)00606-3
  47. Corley, 2009, Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994–2006, Gut, 58, 182, 10.1136/gut.2008.163360 · doi:10.1136/gut.2008.163360
  48. Cook, 2005, A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease, Am J Epidemiol, 162, 1050, 10.1093/aje/kwi325 · DOI · Paper page
  49. Rex, 2003, Screening for Barrett's esophagus in colonoscopy patients with and without heartburn, Gastroenterology, 125, 1670, 10.1053/j.gastro.2003.09.030 · DOI · Paper page
  50. Eloubeidi, 2001, Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans, J Clin Gastroenterol, 33, 306, 10.1097/00004836-200110000-00010 · doi:10.1097/00004836-200110000-00010
  51. Srinivasan, 2004, Profile of GERD in the adult population of a northeast urban community, J Clin Gastroenterol, 38, 651, 10.1097/01.mcg.0000135364.12794.e5 · doi:10.1097/01.mcg.0000135364.12794.e5
  52. Spechler, 2002, Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease, Aliment Pharmacol Ther, 16, 1795, 10.1046/j.1365-2036.2002.01351.x · doi:10.1046/j.1365-2036.2002.01351.x
  53. Eisen, 1997, The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus [see comments], Am J Gastroenterol, 92, 27
  54. Avidan, 2002, Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus, Dig Dis Sci, 47, 256, 10.1023/A:1013797417170 · DOI
  55. Smith, 2005, Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus, Cancer Epidemiol Biomarkers Prev, 14, 2481, 10.1158/1055-9965.EPI-05-0370 · DOI
  56. Lieberman, 1997, Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy, Am J Gastroenterol, 92, 1293
  57. Monaco, 2009, Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors, World J Gastroenterol, 15, 334, 10.3748/wjg.15.334 · DOI
  58. Edelstein, 2007, Central adiposity and risk of Barrett's esophagus, Gastroenterology, 133, 403, 10.1053/j.gastro.2007.05.026 · DOI · Paper page
  59. El Serag, 2005, Abdominal obesity and the risk of Barrett's esophagus, Am J Gastroenterol, 100, 2151, 10.1111/j.1572-0241.2005.00251.x · DOI · Paper page
  60. Kamat, 2009, Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis, Ann Thorac Surg, 87, 655, 10.1016/j.athoracsur.2008.08.003 · doi:10.1016/j.athoracsur.2008.08.003
  61. Corley, 2007, Abdominal obesity and body mass index as risk factors for Barrett's esophagus, Gastroenterology, 133, 34, 10.1053/j.gastro.2007.04.046 · DOI · Paper page
  62. Ronkainen, 2005, Prevalence of Barrett's esophagus in the general population: an endoscopic study, Gastroenterology, 129, 1825, 10.1053/j.gastro.2005.08.053 · DOI · Paper page
  63. Akiyama, 2008, Alcohol consumption is associated with an increased risk of erosive esophagitis and Barrett's epithelium in Japanese men, BMC Gastroenterol, 8, 58, 10.1186/1471-230X-8-58 · doi:10.1186/1471-230x-8-58
  64. Anderson, 2009, The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma, Gastroenterology, 136, 799, 10.1053/j.gastro.2008.12.005 · DOI
  65. Kubo, 2009, Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus, Gastroenterology, 136, 806, 10.1053/j.gastro.2008.11.042 · doi:10.1053/j.gastro.2008.11.042
  66. Kubo, 2009, Cigarette smoking and the risk of Barrett's esophagus, Cancer Causes Control, 20, 303
  67. Thompson, 2009, Vegetable and fruit intakes and risk of Barrett's esophagus in men and women, Am J Clin Nutr, 89, 890, 10.3945/ajcn.2008.26497 · DOI
  68. Kubo, 2008, Dietary patterns and the risk of Barrett's esophagus, Am J Epidemiol, 167, 839, 10.1093/aje/kwm381 · DOI
  69. Rubenstein, 2008, Influence of malpractice history on the practice of screening and surveillance for Barrett's esophagus, Am J Gastroenterol, 103, 842, 10.1111/j.1572-0241.2007.01689.x · doi:10.1111/j.1572-0241.2007.01689.x
  70. Hirota, 2006, ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract, Gastrointest Endosc, 63, 570, 10.1016/j.gie.2006.02.004 · DOI · Paper page
  71. Wang, 2008, Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus, Am J Gastroenterol, 103, 788, 10.1111/j.1572-0241.2008.01835.x · DOI · Paper page
  72. Playford, 2006, New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus, Gut, 55, 442, 10.1136/gut.2005.083600 · doi:10.1136/gut.2005.083600
  73. Corley, 2002, Surveillance and survival in Barrett's adenocarcinomas: a population-based study, Gastroenterology, 122, 633, 10.1053/gast.2002.31879 · DOI · Paper page
  74. Van Sandick, 1998, Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma, Gut, 43, 216, 10.1136/gut.43.2.216 · DOI · Paper page
  75. Inadomi, 2003, Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis [comment], Ann Intern Med, 138, 176, 10.7326/0003-4819-138-3-200302040-00009 · DOI · Paper page
  76. Provenzale, 1999, Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk, Am J Gastroenterol, 94, 2043, 10.1111/j.1572-0241.1999.01276.x · doi:10.1111/j.1572-0241.1999.01276.x · Paper page
  77. Lagergren, 1999, Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma, N Engl J Med, 340, 825, 10.1056/NEJM199903183401101 · DOI · Paper page
  78. Locke, 1997, Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota, Gastroenterology, 112, 1448, 10.1016/S0016-5085(97)70025-8 · DOI · Paper page
  79. Pohl, 2005, The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence, J Natl Cancer Inst, 97, 142, 10.1093/jnci/dji024 · DOI · Paper page
  80. Schnell, 2001, Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia, Gastroenterology, 120, 1607, 10.1053/gast.2001.25065 · doi:10.1053/gast.2001.25065
  81. Eloubeidi, 1999, Does this patient have Barrett's esophagus?, Am J Gastroenterol, 94, 937, 10.1111/j.1572-0241.1999.990_m.x · doi:10.1111/j.1572-0241.1999.990_m.x
  82. Chatelain, 2003, High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins, Virchows Arch, 442, 18, 10.1007/s00428-002-0674-1 · doi:10.1007/s00428-002-0674-1
  83. Montgomery, 2001, Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation, Hum Pathol, 32, 368, 10.1053/hupa.2001.23510 · DOI · Paper page
  84. Shaheen, 2001, Screening strategies in gastroesophageal reflux disease: early identification of esophageal carcinoma, Adv Intern Med, 47, 137
  85. Spechler, 2005, Dysplasia in Barrett's esophagus: limitations of current management strategies, Am J Gastroenterol, 100, 927, 10.1111/j.1572-0241.2005.41201.x · doi:10.1111/j.1572-0241.2005.41201.x
  86. Collard, 2002, High-grade dysplasia in Barrett's esophagus, Chest Surg Clin North Am, 12, 77, 10.1016/S1052-3359(03)00067-X · doi:10.1016/s1052-3359(03)00067-x
  87. Konda, 2008, Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated?, Clin Gastroenterol Hepatol, 6, 159, 10.1016/j.cgh.2007.09.013 · doi:10.1016/j.cgh.2007.09.013
  88. Rastogi, 2008, Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis, Gastrointest Endosc, 67, 394, 10.1016/j.gie.2007.07.019 · doi:10.1016/j.gie.2007.07.019
  89. Schnell, 2001, Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia, Gastroenterology, 120, 1607, 10.1053/gast.2001.25065 · doi:10.1053/gast.2001.25065
  90. Reid, 2000, Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets, Am J Gastroenterol, 95, 1669
  91. Sharma, 2006, Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus, Clin Gastroenterol Hepatol, 4, 566, 10.1016/j.cgh.2006.03.001 · DOI · Paper page
  92. Montgomery, 2001, Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study, Hum Pathol, 32, 379, 10.1053/hupa.2001.23511 · DOI · Paper page
  93. Sharma, 2004, Low-grade dysplasia in Barrett's esophagus, Gastroenterology, 127, 1233, 10.1053/j.gastro.2004.07.061 · doi:10.1053/j.gastro.2004.07.061
  94. Srivastava, 2007, Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus, Am J Gastroenterol, 102, 483, 10.1111/j.1572-0241.2007.01073.x · doi:10.1111/j.1572-0241.2007.01073.x
  95. Fitzgerald, 2001, Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus, Dig Dis Sci, 46, 1892, 10.1023/A:1010678913481 · doi:10.1023/a:1010678913481
  96. Curvers, 2008, Quality of Barrett's surveillance in The Netherlands: a standardized review of endoscopy and pathology reports, Eur J Gastroenterol Hepatol, 20, 601, 10.1097/MEG.0b013e3282f8295d · doi:10.1097/meg.0b013e3282f8295d
  97. Abrams, 2009, Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States, Clin Gastroenterol Hepatol, 7, 736, 10.1016/j.cgh.2008.12.027 · DOI · Paper page
  98. Streitz, 1993, Endoscopic surveillance of Barrett's esophagus, J Thorac Cardiovasc Surg, 105, 383, 10.1016/S0022-5223(19)34219-9 · DOI
  99. Peters, 1994, Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients, J Thorac Cardiovasc Surg, 108, 813, 10.1016/S0022-5223(94)70178-4 · DOI · Paper page
  100. Fountoulakis, 2004, Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer, Br J Surg, 91, 997, 10.1002/bjs.4591 · doi:10.1002/bjs.4591
  101. Cooper, 2002, Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia, Cancer, 95, 32, 10.1002/cncr.10646 · DOI
  102. Cooper, 2009, Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends, Am J Gastroenterol, 104, 1356, 10.1038/ajg.2009.159 · DOI
  103. Kearney, 2003, A case-control study of endoscopy and mortality from adenocarcinoma of the esophagus or gastric cardia in persons with GERD, Gastrointest Endosc, 57, 823, 10.1016/S0016-5107(03)70015-7 · doi:10.1016/s0016-5107(03)70015-7
  104. Rubenstein, 2008, Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans, Gastrointest Endosc, 68, 849, 10.1016/j.gie.2008.02.062 · DOI
  105. Reid, 1988, Observer variation in the diagnosis of dysplasia in Barrett's esophagus, Hum Pathol, 19, 166, 10.1016/S0046-8177(88)80344-7 · DOI · Paper page
  106. Downs-Kelly, 2008, Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies, Am J Gastroenterol, 103, 2333, 10.1111/j.1572-0241.2008.02020.x · doi:10.1111/j.1572-0241.2008.02020.x
  107. Odze, 2006, Diagnosis and grading of dysplasia in Barrett's oesophagus, J Clin Pathol, 59, 1029, 10.1136/jcp.2005.035337 · DOI · Paper page
  108. van Dekken, 2008, Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus, Am J Clin Pathol, 130, 745, 10.1309/AJCPO31THGVEUIDH · doi:10.1309/ajcpo31thgveuidh
  109. Dorer, 2006, AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease, Am J Surg Pathol, 30, 871, 10.1097/01.pas.0000213268.30468.b4 · DOI
  110. Shi, 2008, p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus, Appl Immunohistochem Mol Morphol, 16, 447, 10.1097/PAI.0b013e318168598b · doi:10.1097/pai.0b013e318168598b
  111. Hennig, 2008, Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus, J Mol Med, 86, 233, 10.1007/s00109-007-0271-5 · DOI
  112. Reid, 2000, Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets, Am J Gastroenterol, 95, 1669
  113. Rabinovitch, 2001, Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables, Am J Gastroenterol, 96, 3071, 10.1111/j.1572-0241.2001.05261.x · doi:10.1111/j.1572-0241.2001.05261.x
  114. Kerkhof, 2008, Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus, Cancer Biomark, 4, 1, 10.3233/CBM-2008-4101 · doi:10.3233/cbm-2008-4101
  115. Huang, 2008, Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma, BMC Clin Pathol, 8, 5, 10.1186/1472-6890-8-5 · doi:10.1186/1472-6890-8-5
  116. Rygiel, 2008, Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens, Genes Chromosomes Cancer, 47, 396, 10.1002/gcc.20543 · doi:10.1002/gcc.20543
  117. Reid, 2001, Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression, Am J Gastroenterol, 96, 2839, 10.1111/j.1572-0241.2001.04236.x · doi:10.1111/j.1572-0241.2001.04236.x · Paper page
  118. Galipeau, 2007, NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma, PLoS Med, 4, e67, 10.1371/journal.pmed.0040067 · DOI
  119. Fahmy, 2004, Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens, Mod Pathol, 17, 588, 10.1038/modpathol.3800088 · DOI
  120. Wongsurawat, 2006, Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation, Cancer Epidemiol Biomarkers Prev, 15, 509, 10.1158/1055-9965.EPI-05-0246 · DOI
  121. Cestari, 2007, Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study, Cancer Lett, 251, 278, 10.1016/j.canlet.2006.11.033 · doi:10.1016/j.canlet.2006.11.033
  122. Rygiel, 2007, Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population, Cancer, 109, 1980, 10.1002/cncr.22643 · doi:10.1002/cncr.22643
  123. Schulmann, 2005, Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk, Oncogene, 24, 4138, 10.1038/sj.onc.1208598 · DOI · Paper page
  124. Jin, 2009, A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus, Cancer Res, 69, 4112, 10.1158/0008-5472.CAN-09-0028 · DOI · Paper page
  125. Nelson, 2000, High resolution and high-magnification endoscopy: September 2000, Gastrointest Endosc, 52, 864, 10.1016/S0016-5107(00)70225-2 · doi:10.1016/s0016-5107(00)70225-2
  126. Sharma, 2005, Magnification endoscopy, Gastrointest Endosc, 61, 435, 10.1016/S0016-5107(04)02736-1 · doi:10.1016/s0016-5107(04)02736-1
  127. Yao, 2006, Magnification endoscopy outlines the microvascular architecture and extent of Barrett's intramucosal carcinoma prior to endoscopic resection, Gastrointest Endosc, 63, 1064, 10.1016/j.gie.2006.01.004 · doi:10.1016/j.gie.2006.01.004
  128. Wani, 2007, Endoscopic surface imaging of Barrett's esophagus: an optimistic view, Gastroenterology, 133, 11, 10.1053/j.gastro.2007.05.062 · doi:10.1053/j.gastro.2007.05.062
  129. Kara, 2005, A randomized cross-over study comparing light-induced fluorescence endoscopy with standard video endoscopy for the detection of early neoplasia in Barrett's esophagus, Gastrointest Endosc, 61, 671, 10.1016/S0016-5107(04)02777-4 · doi:10.1016/s0016-5107(04)02777-4
  130. Kara, 2005, High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett's esophagus: a prospective randomized crossover study, Endoscopy, 37, 929, 10.1055/s-2005-870433 · doi:10.1055/s-2005-870433
  131. Canto, 2001, Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study, Endoscopy, 33, 391, 10.1055/s-2001-14427 · doi:10.1055/s-2001-14427
  132. Sharma, 2001, Methylene blue chromoendoscopy for detection of short-segment Barrett's esophagus, Gastrointest Endosc, 54, 289, 10.1067/mge.2001.115728 · doi:10.1067/mge.2001.115728
  133. Breyer, 2003, Does methylene blue detect intestinal metaplasia in Barrett's esophagus?, Gastrointest Endosc, 57, 505, 10.1067/mge.2003.137 · doi:10.1067/mge.2003.137
  134. Horwhat, 2008, A randomized comparison of methylene blue-directed biopsy versus conventional four-quadrant biopsy for the detection of intestinal metaplasia and dysplasia in patients with long-segment Barrett's esophagus, Am J Gastroenterol, 103, 546, 10.1111/j.1572-0241.2007.01601.x · doi:10.1111/j.1572-0241.2007.01601.x
  135. Lim, 2006, Randomized crossover study that used methylene blue or random 4-quadrant biopsy for the diagnosis of dysplasia in Barrett's esophagus, Gastrointest Endosc, 64, 195, 10.1016/j.gie.2005.07.025 · doi:10.1016/j.gie.2005.07.025
  136. Meining, 2004, Inter- and intra-observer variability of magnification chromoendoscopy for detecting specialized intestinal metaplasia at the gastroesophageal junction, Endoscopy, 36, 160, 10.1055/s-2004-814183 · doi:10.1055/s-2004-814183
  137. Sharma, 2003, Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus, Gut, 52, 24, 10.1136/gut.52.1.24 · doi:10.1136/gut.52.1.24
  138. Guelrud, 1998, Acetic acid improves identification of remnant islands of Barrett's epithelium after endoscopic therapy, Gastrointest Endosc, 47, 512, 10.1016/S0016-5107(98)70253-6 · doi:10.1016/s0016-5107(98)70253-6
  139. Ngamruengphong, 2009, Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus: a meta-analysis, Gastrointest Endosc, 69, 1021, 10.1016/j.gie.2008.06.056 · doi:10.1016/j.gie.2008.06.056
  140. Guelrud, 2001, Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus, Gastrointest Endosc, 53, 559, 10.1067/mge.2001.114059 · doi:10.1067/mge.2001.114059
  141. Olliver, 2003, Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus, Lancet, 362, 373, 10.1016/S0140-6736(03)14026-3 · DOI · Paper page
  142. Gono, 2004, Appearance of enhanced tissue features in narrow-band endoscopic imaging, J Biomed Opt, 9, 568, 10.1117/1.1695563 · DOI · Paper page
  143. Pohl, 2007, Comparison of computed virtual chromoendoscopy and conventional chromoendoscopy with acetic acid for detection of neoplasia in Barrett's esophagus, Endoscopy, 39, 594, 10.1055/s-2007-966649 · doi:10.1055/s-2007-966649
  144. Sharma, 2006, The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus, Gastrointest Endosc, 64, 167, 10.1016/j.gie.2005.10.044 · DOI · Paper page
  145. Kara, 2006, Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett's esophagus by using narrow band imaging, Gastrointest Endosc, 64, 155, 10.1016/j.gie.2005.11.049 · doi:10.1016/j.gie.2005.11.049
  146. Curvers, 2008, Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus, Gastroenterology, 134, 670, 10.1053/j.gastro.2008.01.003 · doi:10.1053/j.gastro.2008.01.003
  147. Wolfsen, 2008, Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's esophagus, Gastroenterology, 135, 24, 10.1053/j.gastro.2008.03.019 · doi:10.1053/j.gastro.2008.03.019
  148. Sharma, 2009, Detection of metaplasia and neoplasia in patients with Barrett's esophagus using high-definition white light endoscopy versus narrow band imaging: a prospective, multi-center, randomized, crossover trial, Gastrointest Endosc, 69, AB135, 10.1016/j.gie.2009.03.181 · doi:10.1016/j.gie.2009.03.181
  149. Kara, 2005, Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus, Gastrointest Endosc, 61, 679, 10.1016/S0016-5107(04)02577-5 · doi:10.1016/s0016-5107(04)02577-5
  150. Kara, 2006, Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett's esophagus, Gastrointest Endosc, 64, 176, 10.1016/j.gie.2005.11.050 · doi:10.1016/j.gie.2005.11.050
  151. Curvers, 2008, Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus; a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system, Gut, 57, 167, 10.1136/gut.2007.134213 · doi:10.1136/gut.2007.134213
  152. Kiesslich, 2006, In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy, Clin Gastroenterol Hepatol, 4, 979, 10.1016/j.cgh.2006.05.010 · DOI · Paper page
  153. Pohl, 2008, Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's esophagus, Gut, 57, 1648, 10.1136/gut.2008.157461 · DOI
  154. Meining, 2007, In vivo histopathology for detection of gastrointestinal neoplasia with a portable, confocal miniprobe: an examiner blinded analysis, Clin Gastroenterol Hepatol, 5, 1261, 10.1016/j.cgh.2007.05.019 · doi:10.1016/j.cgh.2007.05.019
  155. Kiesslich, 2004, Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo, Gastroenterology, 127, 706, 10.1053/j.gastro.2004.06.050 · DOI · Paper page
  156. Polglase, 2005, A fluorescence confocal endomicroscope for in vivo microscopy of the upper- and the lower-GI tract, Gastrointest Endosc, 62, 686, 10.1016/j.gie.2005.05.021 · DOI
  157. Becker, 2007, High-resolution miniprobe-based confocal microscopy in combination with video mosaicing (with video), Gastrointest Endosc, 66, 1001, 10.1016/j.gie.2007.04.015 · DOI
  158. Kumagai, 2004, Magnifying chromoendoscopy of the esophagus: in-vivo pathological diagnosis using an endocytoscopy system, Endoscopy, 36, 590, 10.1055/s-2004-814533 · doi:10.1055/s-2004-814533
  159. Pohl, 2007, Evaluation of endocytoscopy in the surveillance of patients with Barrett's esophagus, Endoscopy, 39, 492, 10.1055/s-2007-966340 · doi:10.1055/s-2007-966340
  160. Georgakoudi, 2001, Fluorescence, reflectance and light scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus, Gastroenterology, 120, 1620, 10.1053/gast.2001.24842 · doi:10.1053/gast.2001.24842
  161. Ortner, 2003, Time gated fluorescence spectroscopy in Barrett's oesophagus, Gut, 52, 28, 10.1136/gut.52.1.28 · DOI
  162. Wallace, 2000, Endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattering spectroscopy, Gastroenterology, 119, 677, 10.1053/gast.2000.16511 · DOI · Paper page
  163. Kobayashi, 1998, High-resolution cross-sectional imaging of the gastrointestinal tract using optical coherence tomography: preliminary results, Gastrointest Endosc, 47, 515, 10.1016/S0016-5107(98)70254-8 · doi:10.1016/s0016-5107(98)70254-8
  164. Bouma, 2000, High-resolution imaging of the human esophagus and stomach in vivo using optical coherence tomography, Gastrointest Endosc, 51, 467, 10.1016/S0016-5107(00)70449-4 · doi:10.1016/s0016-5107(00)70449-4
  165. Poneros, 2001, Diagnosis of specialized metaplasia by optical coherence tomography, Gastroenterology, 120, 7, 10.1053/gast.2001.20911 · doi:10.1053/gast.2001.20911
  166. Evans, 2006, Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus, Clin Gastroenterol Hepatol, 4, 38, 10.1016/S1542-3565(05)00746-9 · doi:10.1016/s1542-3565(05)00746-9
  167. Qi, 2006, Computer-aided diagnosis of dysplasia in Barrett's esophagus using endoscopic optical coherence tomography, J Biomed Opt, 11, 044010, 10.1117/1.2337314 · doi:10.1117/1.2337314
  168. Kelloff, 2006, Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward, Clin Cancer Res, 12, 3661, 10.1158/1078-0432.CCR-06-1104 · DOI · Paper page
  169. Fitzgerald, 1996, Dynamic effects of acid on Barrett's esophagus, J Clin Invest, 98, 2120, 10.1172/JCI119018 · DOI · Paper page
  170. Shirvani, 2000, Cyclooxygenase 2 expression in Barrett's Esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure, Gastroenterology, 118, 487, 10.1016/S0016-5085(00)70254-X · DOI · Paper page
  171. Souza, 2002, Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus, Gastroenterology, 122, 299, 10.1053/gast.2002.30993 · DOI · Paper page
  172. Clemons, 2007, Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms, Gastroenterology, 133, 1198, 10.1053/j.gastro.2007.06.061 · DOI
  173. El Serag, 2004, Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus, Am J Gastroenterol, 99, 1877, 10.1111/j.1572-0241.2004.30228.x · DOI · Paper page
  174. Hillman, 2004, Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus, Med J Aust, 180, 387, 10.5694/j.1326-5377.2004.tb05991.x · DOI · Paper page
  175. Cooper, 2006, Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence, Aliment Pharmacol Ther, 23, 727, 10.1111/j.1365-2036.2006.02825.x · DOI
  176. Ouatu-Lascar, 1999, Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression, Gastroenterology, 117, 327, 10.1053/gast.1999.0029900327 · DOI · Paper page
  177. Peters, 2000, Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus, Scand J Gastroenterol, 35, 1238, 10.1080/003655200453557 · doi:10.1080/003655200453557
  178. Umansky, 2001, Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus, Oncogene, 20, 7987, 10.1038/sj.onc.1204947 · DOI
  179. García Rodríguez, 2006, Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK, Gut, 55, 1538, 10.1136/gut.2005.086579 · DOI
  180. Chow, 1995, The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia, JAMA, 274, 474, 10.1001/jama.1995.03530060048032 · DOI · Paper page
  181. Garrow, 2000, Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer, Cancer Causes Control, 11, 231
  182. Molina, 1999, Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs, Cancer Res, 59, 4356
  183. Piazza, 1995, Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis, Cancer Res, 55, 3110
  184. Souza, 2000, Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells, Cancer Research, 60, 5767
  185. Buttar, 2002, The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study, J Natl Cancer Inst, 94, 422, 10.1093/jnci/94.6.422 · DOI
  186. Aggarwal, 2000, Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression, Neoplasia, 2, 346, 10.1038/sj.neo.7900097 · DOI
  187. von Rahden, 2005, Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma, Cancer Res, 65, 5038, 10.1158/0008-5472.CAN-04-1107 · DOI
  188. Buttar, 2002, Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus, Gastroenterology, 122, 1101, 10.1053/gast.2002.32371 · DOI · Paper page
  189. Oyama, 2005, A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats, Carcinogenesis, 26, 565, 10.1093/carcin/bgh340 · DOI
  190. Kim, 2007, Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats, Yonsei Med J, 48, 1020, 10.3349/ymj.2007.48.6.1020 · doi:10.3349/ymj.2007.48.6.1020
  191. Kaur, 2002, Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus, Gastroenterology, 123, 60, 10.1053/gast.2002.34244 · doi:10.1053/gast.2002.34244
  192. Corley, 2003, Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis, Gastroenterology, 124, 47, 10.1053/gast.2003.50008 · DOI · Paper page
  193. Abnet, 2009, Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis, Br J Cancer, 100, 551, 10.1038/sj.bjc.6604880 · DOI
  194. Vaughan, 2005, Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study, Lancet Oncol, 6, 945, 10.1016/S1470-2045(05)70431-9 · DOI
  195. Heath, 2007, Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial, J Natl Cancer Inst, 99, 545, 10.1093/jnci/djk112 · DOI
  196. McQuaid, 2006, Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials, Am J Med, 119, 624, 10.1016/j.amjmed.2005.10.039 · DOI · Paper page
  197. Chan, 2001, Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen, N Engl J Med, 344, 967, 10.1056/NEJM200103293441304 · DOI · Paper page
  198. Lai, 2003, Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use, N Engl J Med, 346, 2033, 10.1056/NEJMoa012877 · DOI · Paper page
  199. 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, 71, 10.1136/bmj.324.7329.71 · DOI · Paper page
  200. Hayden, 2002, Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force, Ann Intern Med, 136, 161, 10.7326/0003-4819-136-2-200201150-00016 · DOI · Paper page

200 of 315 shown

Cited by

See all 1,060

Metadata

Authors
Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M., & Shaheen, N. J.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2011-03
Volume
140
Issue
3
Pages
e18-e52
ISSN
0016-5085 (ISSN-L)
DOI
10.1053/j.gastro.2011.01.031
OpenAlex
W2024455739
Cited by
1,060
References
3
FWCI
95.53
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus. https://app.cochat.ai/papers/10.1053/j.gastro.2011.01.031
The paper
Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M., & Shaheen, N. J. (2011). American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus. Gastroenterology. https://doi.org/10.1053/j.gastro.2011.01.031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.